CYLD Monoclonal Antibody (733), Invitrogen™
Manufacturer: Invitrogen
Select a Size
| Pack Size | SKU | Availability | Price |
|---|---|---|---|
| Each of 1 | 43-770-0-Each-of-1 | In Stock | ₹ 44,500.00 |
43-770-0 - Each of 1
In Stock
Quantity
1
Base Price: ₹ 44,500.00
GST (18%): ₹ 8,010.00
Total Price: ₹ 52,510.00
Antigen
CYLD
Classification
Monoclonal
Concentration
0.5 mg/mL
Formulation
PBS with 0.1% sodium azide; pH 7.4
Gene Accession No.
Q1RMU2, Q66H62, Q80TQ2, Q9NQC7
Gene Symbols
CYLD
Immunogen
Recombinant protein derived from the N-terminus of human CYLD protein
Quantity
100 μg
Primary or Secondary
Primary
Target Species
Bovine, Equine, Human, Mouse, Non-human Primate, Rat
Product Type
Antibody
Isotype
IgG1
Applications
Immunocytochemistry, Immunohistochemistry (Paraffin), Western Blot
Clone
733
Conjugate
Unconjugated
Gene
CYLD
Gene Alias
2010013M14Rik; 2900009M21Rik; BRSS; C130039D01Rik; CDMT; Cyld; CYLD lysine 63 deubiquitinase; CYLD1; CYLDI; cylindromatosis (turban tumor syndrome); deubiquitinating enzyme CYLD; EAC; FLJ20180; FLJ31664; FLJ78684; HSPC057; KIAA0849; LRRGT00003; MFT; MFT1; mKIAA0849; probable ubiquitin carboxyl-terminal hydrolase CYLD; retinitis pigmentosa 1 homolog; Rp1; Rp1h; SBS; TEM; ubiquitin carboxyl-terminal hydrolase CYLD; ubiquitin specific peptidase like 2; ubiquitin thioesterase CYLD; ubiquitin thiolesterase CYLD; ubiquitin-specific-processing protease CYLD; Unknown (protein for MGC:137952); USPL2
Host Species
Mouse
Purification Method
Protein A
Regulatory Status
RUO
Gene ID (Entrez)
100050308, 1540, 312937, 536421, 74256
Content And Storage
Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.
Form
Liquid
Related Products
Description
- CYLD is a 956 aa, cytoplasmic, deubiquitinating enzyme belonging to the ubiquitin carboxy-terminal hydrolases (UCH) family of proteins with three cytoskeletal-associated protein-glycine-conserved (CAP-GLY) domains, a proline rich region, a SH3 binding domain and a sequence homology to catalytic domain of UCH
- CYLD is identified as a tumor suppressor protein affecting the JNK signaling pathway
- CYLD is a negative regulator of TRAF2 and NF-kappa-B signaling pathway and is also known to have receptor-dependent role in regulating the I-kappa-B kinase pathway
- It also has a deubiquitinating activity that is directed towards non-Lys-48-linked polyubiquitin chains and TRAP1 is a novel substrate for deubiquitination
- Mutated CYLD is known to be associated with cylindromatosis, multiple familial trichoepithelioma, and Brooke-Spiegler syndrome.